The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin
Open accessAbstract
OBJECTIVE: Cases of acute pancreatitis have been reported in association with exenatide, sitagliptin, and type 2 diabetes without use of these medications. It remains unknown whether exenatide or sitagliptin increase the risk of acute pancreatitis. RESEARCH DESIGN AND METHODS: A retrospective cohort study of a large medical and pharmacy claims database was performed. Data for 786,656 patients were analyzed. Cox proportional hazard models were built to compare the risk of acute pancreatitis between diabetic and nondiabetic subjects and between exenatide, sitagliptin, and control diabetes medication use. RESULTS: Incidence of acute pancreatitis in the nondiabetic control group, diabetic control group, exenatide group, and sitagliptin group was 1.9, 5.6, 5.7, and 5.6 cases per 1,000 patient years, respectively. The risk of acute pancreatitis was significantly higher in the combined diabetic groups than in the nondiabetic control group (adjusted hazard ratio 2.1 [95% CI 1.7–2.5]). Risk of acute pancreatitis was similar in the exenatide versus diabetic control group (0.9 [0.6–1.5]) and sitagliptin versus diabetic control group (1.0 [0.7–1.3]). CONCLUSIONS: Our study demonstrated increased incidence of acute pancreatitis in diabetic versus nondiabetic patients but did not find an association between the use of exenatide or sitagliptin and acute pancreatitis. The limitations of this observational claims-based analysis cannot exclude the possibility of an increased risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A chronic disease score from automated pharmacy data
Von Korff, M., Wagner, E. H., & Saunders, K. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90016-g · Cited by 961
Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 Diabetes
Noel, R. A., Braun, D. K., Patterson, R. E., & Bloomgren, G. L. (2009) · Diabetes Care · doi:10.2337/dc08-1755 · Cited by 435
Dore, D. D., Seeger, J. D., & Arnold Chan, K. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902820519 · Cited by 326
Weighing Risks and Benefits of Liraglutide — The FDA's Review of a New Antidiabetic Therapy
Parks, M., & Rosebraugh, C. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1001578 · Cited by 275
Matveyenko, A. V., Dry, S., Cox, H. I., Moshtaghian, A., Gurlo, T., Galasso, R., Butler, A. E., & Butler, P. C. (2009) · Diabetes · doi:10.2337/db09-0058 · Cited by 242
Girman, C. J., Kou, T. D., Cai, B., Alexander, C. M., O’Neill, E. A., Williams‐Herman, D. E., & Katz, L. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01231.x · Cited by 212
Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas
Nachnani, J. S., Bulchandani, D. G., Nookala, A., Herndon, B., Molteni, A., Pandya, P., Taylor, R., Quinn, T., Weide, L., & Alba, L. M. (2010) · Diabetologia · doi:10.1007/s00125-009-1515-4 · Cited by 189
Exenatide (Exendin-4)–Induced Pancreatitis
Denker, P. S., & Dimarco, P. E. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-2043 · Cited by 140
Exenatide and Rare Adverse Events
Cure, P., Pileggi, A., & Alejandro, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmc0707137 · Cited by 134
Exenatide and rare adverse events.
Ahmad, S. R., & Swann, J. (2008) · PubMed · Cited by 122
Cited by
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62154-6 · Cited by 1,743
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944
Update on the treatment of type 2 diabetes mellitus
Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560
Singh, S., Chang, H.-Y., Richards, T. M., Weiner, J. P., Clark, J. M., & Segal, J. B. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.2720 · Cited by 467
A Critical Analysis of the Clinical Use of Incretin-Based Therapies
Butler, P. C., Elashoff, M., Elashoff, R., & Gale, E. A. M. (2013) · Diabetes Care · doi:10.2337/dc12-2713 · Cited by 296
Smits, M. M., & Van Raalte, D. H. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645563 · Cited by 332
Diabetes and cancer: two diseases with obesity as a common risk factor
Garg, S. K., Maurer, H., Reed, K., & Selagamsetty, R. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12124 · Cited by 275
Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis
Pedersen, S. B., Langsted, A., & Nordestgaard, B. G. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.6875 · Cited by 270
Li, L., Shen, J., Bala, M. M., Busse, J. W., Ebrahim, S., Vandvik, P. O., Rios, L. P., Malaga, G., Wong, E., Sohani, Z., et al. (2014) · BMJ · doi:10.1136/bmj.g2366 · Cited by 254
Preservation of β-Cell Function: The Key to Diabetes Prevention
DeFronzo, R. A., & Abdul-Ghani, M. A. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0246 · Cited by 247
Monami, M., Nreu, B., Scatena, A., Cresci, B., Andreozzi, F., Sesti, G., & Mannucci, E. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12926 · Cited by 243
Alves, C., Batel-Marques, F., & Macedo, A. F. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.09.008 · Cited by 186
Seufert, J., & Gallwitz, B. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12251 · Cited by 156
Do GLP-1–Based Therapies Increase Cancer Risk?
Nauck, M. A., & Friedrich, N. (2013) · Diabetes Care · doi:10.2337/dcs13-2004 · Cited by 145
Seino, Y., Terauchi, Y., Osonoi, T., Yabe, D., Abe, N., Nishida, T., Zacho, J., & Kaneko, S. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13082 · Cited by 127
Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis
Azoulay, L., Filion, K. B., Platt, R. W., Dahl, M., Dormuth, C. R., Clemens, K. K., Durand, M., Hu, N., Juurlink, D. N., Paterson, J. M., et al. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.1522 · Cited by 120
Monami, M., Dicembrini, I., Nardini, C., Fiordelli, I., & Mannucci, E. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.01.010 · Cited by 106
Lando, H. M., Alattar, M., & Dua, A. P. (2012) · Endocrine Practice · doi:10.4158/ep11290.or · Cited by 102
Vrang, N., Jelsing, J., Simonsen, L., Jensen, A. E., Thorup, I., Søeborg, H., & Knudsen, L. B. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00182.2012 · Cited by 92
Thomsen, R. W., Pedersen, L., Møller, N., Kahlert, J., Beck-Nielsen, H., & Sørensen, H. T. (2015) · Diabetes Care · doi:10.2337/dc13-2983 · Cited by 89
Guideline Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
Raz, I. (2013) · Diabetes Care · doi:10.2337/dcs13-2035 · Cited by 71
The French Pharmacovigilance Centers Network, Faillie, J.-L., Babai, S., Crépin, S., Bres, V., Laroche, M.-L., Le Louet, H., Petit, P., Montastruc, J.-L., & Hillaire-Buys, D. (2013) · Acta Diabetologica · doi:10.1007/s00592-013-0544-0 · Cited by 70
GLP-1R agonist therapy for diabetes: benefits and potential risks
Samson, S. L., & Garber, A. (2013) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32835edb32 · Cited by 55
Jensen, T. M., Saha, K., & Steinberg, W. M. (2015) · Diabetes Care · doi:10.2337/dc13-1210 · Cited by 48
An Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers
Tseng, C.-H., Lee, K.-Y., & Tseng, F.-H. (2015) · Journal of Environmental Science and Health, Part C · doi:10.1080/10590501.2015.1003496 · Cited by 49
Nauck, M. A., Frossard, J.-L., Barkin, J. S., Anglin, G., Hensley, I. E., Harper, K. D., & Milicevic, Z. (2017) · Diabetes Care · doi:10.2337/dc16-0984 · Cited by 36
Mechanism of glucagon-like peptide 1 improvements in type 2 diabetes mellitus and obesity.
Nolen-Doerr, E., Stockman, M.-C., & Rizo, I. (2019) · Current Obesity Reports · doi:10.1007/s13679-019-00350-4 · Cited by 32
Tokuyama, H., Kawamura, H., Fujimoto, M., Kobayashi, K., Nieda, M., Okazawa, T., Takemoto, M., & Shimada, F. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.03.034 · Cited by 24
Acute pancreatitis due to different semaglutide regimens: An updated meta-analysis
Masson, W., Lobo, M., Barbagelata, L., Lavalle-Cobo, A., & Nogueira, J. P. (2024) · Endocrinología, Diabetes y Nutrición (English ed.) · doi:10.1016/j.endien.2024.03.012 · Cited by 22
Peng, H., Want, L. L., & Aroda, V. R. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0728-4 · Cited by 20
Gallwitz, B. (2013) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018813486165 · Cited by 20
Moore, N. (2011) · BMJ · doi:10.1136/bmj.d2732 · Cited by 5
Metadata
- Authors
- Garg, R., Chen, W., & Pendergrass, M.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2010-08-03
- Volume
- 33
- Issue
- 11
- Pages
- 2349-2354
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2164535707
- Cited by
- 322
- References
- 14
- FWCI
- 46.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.